InsidersTradesSigma
PHARMANUTRA PHARMANUTRA S.P.A.: CDA APPROVA IL RESOCONTO INTERMEDIO DI GESTIONE AL 30 SETTEMBRE 2025 Stock: price and management transactions · Italy · Consob
CONSOB:pharmanutra-pharmanutra-spa-cda-approva-il-resoconto-intermedio-di-gestione-al-3-f4e316·ConsobHealth Care
Follow the PHARMANUTRA PHARMANUTRA S.P.A.: CDA APPROVA IL RESOCONTO INTERMEDIO DI GESTIONE AL 30 SETTEMBRE 2025 stock price and the full insider trade history of the company, a listed issuer based in Italy. Shares are listed on IT IT, under the supervision of Consob. Operating in the Health Care sector, PHARMANUTRA PHARMANUTRA S.P.A.: CDA APPROVA IL RESOCONTO INTERMEDIO DI GESTIONE AL 30 SETTEMBRE 2025 has logged 0 reports. Every trade is openly available.
n/a
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Declarations0 total
No declarations found
0 of 0 declarations
About PHARMANUTRA PHARMANUTRA S.P.A.: CDA APPROVA IL RESOCONTO INTERMEDIO DI GESTIONE AL 30 SETTEMBRE 2025
PHARMANUTRA S.P.A. is a company operating in the health and pharmaceutical sector. It has recently received approval for its interim management report as of September 30, 2025.